GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » EV-to-Revenue

ProQR Therapeutics NV (ProQR Therapeutics NV) EV-to-Revenue : 7.96 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ProQR Therapeutics NV's enterprise value is $56.12 Mil. ProQR Therapeutics NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $7.05 Mil. Therefore, ProQR Therapeutics NV's EV-to-Revenue for today is 7.96.

The historical rank and industry rank for ProQR Therapeutics NV's EV-to-Revenue or its related term are showing as below:

PRQR' s EV-to-Revenue Range Over the Past 10 Years
Min: -51.35   Med: 7.88   Max: 1481.97
Current: 7.96

During the past 12 years, the highest EV-to-Revenue of ProQR Therapeutics NV was 1481.97. The lowest was -51.35. And the median was 7.88.

PRQR's EV-to-Revenue is ranked better than
50.82% of 1039 companies
in the Biotechnology industry
Industry Median: 8.37 vs PRQR: 7.96

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-11), ProQR Therapeutics NV's stock price is $1.98. ProQR Therapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.09. Therefore, ProQR Therapeutics NV's PS Ratio for today is 22.76.


ProQR Therapeutics NV EV-to-Revenue Historical Data

The historical data trend for ProQR Therapeutics NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV EV-to-Revenue Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 282.95 58.18 7.45

ProQR Therapeutics NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.18 14.20 4.15 -0.11 7.45

Competitive Comparison of ProQR Therapeutics NV's EV-to-Revenue

For the Biotechnology subindustry, ProQR Therapeutics NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's EV-to-Revenue falls into.



ProQR Therapeutics NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ProQR Therapeutics NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=56.116/7.05
=7.96

ProQR Therapeutics NV's current Enterprise Value is $56.12 Mil.
ProQR Therapeutics NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProQR Therapeutics NV  (NAS:PRQR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ProQR Therapeutics NV's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.98/0.087
=22.76

ProQR Therapeutics NV's share price for today is $1.98.
ProQR Therapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProQR Therapeutics NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.